<DOC>
	<DOCNO>NCT01378988</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetic , pharmacodynamic , safety dexmedetomidine 2 different dose level pediatric subject , age 12 month &lt; 24 month , administer intravenous load dose follow continuous infusion minimum 6 hour 24 hour intensive care set .</brief_summary>
	<brief_title>Phase II Pharmacokinetic Pharmacodynamic Study DEX Subjects Aged 12 Months Through &lt; 24 Months</brief_title>
	<detailed_description>Phase II , randomize , open-label , single-center , study evaluate pharmacokinetics pharmacodynamics dexmedetomidine pediatric subject across two dose level ( Dose Level 1 consist 0.7 mcg/kg load dose immediately follow 0.5 mcg/kg/hr maintenance infusion ; Dose Level 2 consist 1.0 mcg/kg load dose immediately follow 0.75 mcg/kg/hr maintenance infusion ) . The study population consist intubate mechanically ventilate pediatric subject require sedation intensive care set minimum 6 hour exceed 24 hour . Subjects eligible enrollment 12 month &lt; 24 month age .</detailed_description>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>1 . Subject 12 month &lt; 24 month age screening . 2 . Subject intubate mechanically ventilated intensive care set anticipate require minimum 6 hour continuous IV sedation . 3 . Subject adequate renal function , define : Serum creatinine ≤1.0 mg/dL . 4 . The subject 's parent ( ) legal guardian ( ) must voluntarily sign date inform consent document approve Institutional Review Board . 1 . Pediatric subject neurological condition prohibit evaluation sedation : Diminished consciousness increase intracranial pressure Extensive brain surgery ( surgery require intracranial pressure monitor ) Diminished cognitive function per Principal Investigator ( PI ) discretion Subjects immobility neuromuscular disease continuous infusion neuromuscular block agent . 2 . Subjects second degree third degree heart block unless subject permanent pacemaker pace wire situ . 3 . Subjects hepatic impairment define serum glutamicpyruvic transaminase/alanine aminotransferase ( SGPT/ALT ) &gt; 90 U/L time screen . 4 . Subjects hypotension , base repeat assessment within 15 minute precede start study drug , define : Systolic blood pressure ( SBP ) &lt; 70 mmHg . 5 . Preexisting bradycardia base repeated assessment within 15 minute precede start study drug , define : Heart rate ( HR ) &lt; 70 bpm . 6 . Subject acute thermal burn involve 15 percent total body surface area . 7 . Subjects know allergy dexmedetomidine , midazolam fentanyl . 8 . Subject receive dexmedetomidine within 15 hour prior start study drug . 9 . Subjects life expectancy &lt; 72 hour . 10 . Subjects expect hemodialysis ( continuous hemofiltration ) , peritoneal dialysis extracorporeal membrane oxygenation ( ECMO ) treatment within 48 hour prior start study drug duration study . 11 . Subjects treat α2 agonists/antagonists within 2 week . 12 . Subjects spinal cord injury T5 ( 5th Thoracic Vertebra ) . 13 . Subjects receive another investigational drug part investigational drug study within past 30 day . 14 . Subjects , opinion investigator , may able comply safety monitoring requirement clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>